HPS Pharmacies wish to advise that Janssen-Cilag is experiencing a supply interruption for some of their methylphenidate hydrochloride modified-release tablets (Concerta®), and is anticipating shortages for other strengths. The other supplier of modified-release methylphenidate tablets, Teva Pharma, is also experiencing a supply interruption.
The products affected by this notice are shown in the table below.
| Product | ARTG | Current Status |
| Concerta® 18mg | 93862 | Current – end-May 2025 |
| Concerta® 27mg | 124502 | Mid-December – end-May 2025 |
| Concerta® 36mg | 93863 | Mid-December – end-May 2025 |
| Concerta® 54mg | 93864 | Current – end-May 2025 |
| Methylphenidate-Teva XR 18 mg | 370912 | Current – mid-December 2024 |
| Methylphenidate-Teva XR 54 mg | 370899 | Current – mid-December 2024 |
Other forms of methylphenidate, such as immediate-release tablets and modified-release capsules, remain available. The Therapeutic Goods Administration (TGA) provides further information on the methylphenidate shortage.
Retain this notice in a prominent position, including in other related business units until supplies return to normal. Report any problems identified with medicines, vaccines or medical devices to the TGA.
Should you require further information regarding this matter, please contact your pharmacist at HPS Pharmacies.
Subscribe Knowledge Centre Updates
Enter your details to receive Knowledge Centre updates